EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Approach to the Patient: Low Testosterone Concentrations in Men With Obesity

Christopher A Muir iD, Gary A Wittert iD, David J Handelsman

The Journal of Clinical Endocrinology & Metabolism · 07.08.2025 · 110 (9) · e3125-e3130

DOI: 10.1210/clinem/dgaf137 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 07.03.2025. Verfasst von Christopher A Muir und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Andrology, Concord Repatriation General Hospital, Sydney, NSW 2139, Australia. Hauptthemen laut MEDLINE: Testosterone, Obesity, Hypogonadism. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathologic hypogonadism occurs when serum testosterone is significantly and persistently reduced by irreversible organic (structural, genetic) disorders of the hypothalamic pituitary testicular axis. Men with pathologic hypogonadism require lifelong testosterone replacement. In contrast, mild or moderate reductions in serum testosterone frequently accompany obesity, and its numerous comorbidities in men are best considered nongonadal illness syndromes, wherein reduction in serum testosterone is usually reversible upon amelioration of the underlying nongonadal illness. Obesity can result in nonspecific symptoms in conjunction with reduced serum testosterone and serum SHBG. Obesity-related reductions in SHBG, testosterone's principal circulating carrier protein, are primarily responsible for measured reductions in testosterone. However, obesity is not a cause of pathological hypogonadism, and proportionately reduced testosterone and SHBG concentrations accompanied by normal serum LH and FSH concentrations confirm a eugonadal state, best described as the pseudo-hypogonadism of obesity. Herein we demonstrate how clinically significant weight loss substantially reverses obesity-related reductions in serum testosterone and ameliorates nonspecific symptoms resembling, but not due to, androgen deficiency. The important reversible steps include weight reduction and optimizing management of type 2 diabetes mellitus, obstructive sleep apnea, depression, and other obesity-related comorbidities as well as rationalizing concomitant drug regimens. In the absence of pathological hypogonadism, testosterone treatment is less effective than a diet and lifestyle intervention to rectify the reversible conditions responsible for the nonspecific symptoms and associated reduced serum testosterone concentrations observed in men with obesity. As such, testosterone treatment is not indicated, and unwarranted off-label testosterone treatment can lead to adverse effects such as infertility, elevated hematocrit requiring venesection, a prothrombotic state, and testosterone dependence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TestosteroneObesityHypogonadismHumansMaleWeight LossMiddle AgedAdultDiabetes Mellitus, Type 2Hormone Replacement Therapy

Stichwörter der Autor:innen

androgen deficiencyhypogonadismobesitytestosterone

Substanzen

Testosterone

Autor:innen und Institutionen

  • Department of Andrology, Concord Repatriation General Hospital, Sydney, NSW 2139, Australia.
  • Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2050, Australia.
  • School of Clinical Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
  • South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia.
  • Freemasons Centre for Male Health and Wellbeing, University of Adelaide, Adelaide, SA 5000, Australia.
  • ANZAC Research Institute, University of Sydney, Sydney, NSW 2138, Australia.

ORCID-Profile: Christopher A Muir, Gary A Wittert

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Muir, C. A., Wittert, G. A., & Handelsman, D. J. (2025). Approach to the Patient: Low Testosterone Concentrations in Men With Obesity. The Journal of Clinical Endocrinology & Metabolism, 110(9), e3125-e3130. https://doi.org/10.1210/clinem/dgaf137

Vancouver

Muir CA, Wittert GA, Handelsman DJ. Approach to the Patient: Low Testosterone Concentrations in Men With Obesity. The Journal of Clinical Endocrinology & Metabolism. 2025;110(9):e3125-e3130. doi:10.1210/clinem/dgaf137

BibTeX
@article{Muir2025,
  author = {Muir, Christopher A and Wittert, Gary A and Handelsman, David J},
  title = {Approach to the Patient: Low Testosterone Concentrations in Men With Obesity},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {9},
  pages = {e3125--e3130},
  doi = {10.1210/clinem/dgaf137}
}
Kostenlos starten →